New study aims to cut unnecessary prostate biopsies with MRI
NCT ID NCT04993508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to diagnose prostate cancer using PSA tests, digital rectal exams, and MRI scans. Men aged 50-75 with elevated PSA or suspicious exams will get an MRI first. Only those with suspicious MRI results will have a biopsy, and they will be randomly assigned to either MRI-targeted biopsy alone or combined with standard systematic biopsy. The goal is to see if targeted biopsy alone can find serious cancers while avoiding unnecessary detection of low-risk cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could make prostate cancer diagnosis more accurate, reducing unnecessary biopsies and overtreatment.
What could go wrong
This is an early-stage study not yet recruiting, and results may not apply to all men or settings. MRI-targeted biopsy might miss some cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••